Answers are grounded in this paper and cite their sources.
Targeting ERLIN1 reveals a coordinated cholesterol-dependent vulnerability in hepatocellular carcinoma" published in Clinical and Molecular Hepatology.1,2 Their commentary highlights the importance of cholesterol metabolic dysregulation in hepatocellular car-cinoma (HCC) and provides valuable perspectives on the role of ERLIN1 in maintaining cholesterol homeostasis as well as its potential therapeutic implications.HCC with metabolic disorders such as metabolic dysfunction-associated steatohepatitis (MASH) presents new challenges to existing targeted therapies and immunotherapies.3 Therefore, identifying novel metabolic vulnerabilities as therapeutic targets is urgently needed.Cholesteroldysregulated HCC is a malignant subtype we previously Fine-tuning cholesterol metabolic reprogramming via ERLIN1 in hepatocellular carcinoma: Correspondence to editorial on "Targeting ER lipid raft-associated 1 reveals a coordinated cholesterol-dependent vulnerability in hepatocellular carcinoma"
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: